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Abstract: In response to environmental cues the human pathogen Staphylococcus aureus 
synthesizes and releases proteinaceous enterotoxins. These enterotoxins are natural 
etiologic entities of severe food poisoning, toxic shock syndrome, and acute diseases. 
Staphylococcal enterotoxins are currently listed as Category B Bioterrorism Agents by the 
Center for Disease Control and Prevention. They are associated with respiratory illnesses, 
and may contribute to exacerbation of pulmonary disease. This likely stems from the 
ability of Staphylococcal enterotoxins to elicit powerful episodes of T cell stimulation 
resulting in release of pro-inflammatory cytokines. Here, we discuss the role of the immune 
system and potential mechanisms of disease initiation and progression. 
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1. Introduction 
Bacterial enterotoxins are proteinaceous toxins primarily ranging between 23–30 kDa that typically 
enter the body through mucosal sites. Unlike conventional antigens, enterotoxins can bypass antigen 
processing by binding to a specific groove outside the usual peptide-binding site of Major 
Histocompatibility class II (MHC II). These enterotoxins are often known as superantigens (SAgs) for 
their ability to bridge MHC II with the T cell receptor (TCR) unleashing robust T cell activation. In 
this review, we will examine the specificity of SAgs, their powerful effects on T cells, and   
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their potential to induce strong pulmonary immune responses. The enterotoxins produced by 
Staphylococcus aureus will be emphasized since this pathogen is an emerging health concern in the 
living environment, hospitals, and as a co-infection. 
2. Mechanism of Action on T Cells 
Conventional antigen presentation requires protein processing and peptide binding to MHC I or MHC 
II followed by interactions with the combined interface of the TCRα and β chains. In contrast, SAg binds 
directly to the Vβ region of the TCR. Typically a particular SAg has specificity for more than one TCR 
Vβ chain and this is well documented for enterotoxins derived from Staphylococcus aureus (Table 1). 
Unlike MHC I and II restricted antigen presentation, both CD4 and CD8 T cells with specific TCR Vβ 
chains can be activated by SAgs. The oligoclonal nature of such stimulation activates a high proportion 
of T cells. Hence in human and mice, SAg elicits a powerful T cell response, characterized by robust 
proliferation and release of effector cytokines. Superantigen-stimulated T cells typically undergo 5–6 
rounds of cell division [1] and activation status is clearly indicated by upregulation of surface CD69 [2]. 
Production of IFN-γ, TNF and other pro-inflammatory cytokines can be detected [1,2]. SEA-stimulated 
CD8 T cells exhibit cytotoxic killer phenotype that correlates with granzyme B and perforin expression [3]. 
Therefore, natural SAg responses are similar to artificial triggering by CD3 ligation. 
Table 1. T cell receptor Vβ specificity of SE SAgs in mouse and human. 
  Mouse TCR Vβ  Human TCR Vβ 
SEA  1, 3, 10, 11, 17 
1.1, 5.1, 5.2, 5.3, 6.3, 6.4, 6.9, 7.2, 7.3, 7.4, 7.9, 8, 9.1, 16, 
18, 21.3, 22, 23.1 
SEB  3, 7, 8.1, 8.2, 8.3, 17  1.1, 3.2, 6.4, 12, 13.2, 14, 15.1, 17, 20, 22 
SEC1  3, 8.2, 8.3, 11, 17  3.2, 6.4, 6.9, 12, 15.1 
SEC2  3, 8.2, 10, 17  12, 13.1, 13.2, 14, 15, 17, 20 
SEC3  3, 7, 8.1, 8.2  5.1, 12 
SED  3, 7, 8.1, 8.2, 8.3, 11, 17  1.1, 5.3, 6.9, 7.4, 8.1, 12.1 
SEE  11, 15, 17  5.1, 6.1, 6.2, 6.3, 6.4, 6.7, 6.9, 8.1, 16, 18, 21.3 
SEG    3, 12, 13.1, 13.2, 13.6, 14, 15 
SEH    10 
SEI    1.1, 5.1, 5.2, 5.3, 6b, 23.1 
SEJ     
SElK    5.1, 5.2, 5.3, 6.7, 21.3, 23 
SElL    5.1, 5.2, 5.3, 6.7, 7.9, 9, 16, 22, 23 
SElM    5.1, 5.2, 5.3, 6a, 6b, 7.1, 8, 9, 18, 21.3, 23 
SElN    5.1, 5.2, 5.3, 9, 20 
SElO    5.1, 7.1, 21.3 
SElP    5.1, 6, 8, 16, 18, 21.3 
SElQ    2.1, 5.1, 5.2, 6.7, 21.3 
SElR    3, 5.1, 8, 11, 12, 13.2, 14 
SElU    12, 13.2, 14 
SES    9, 16 
SET     
TSST-1  3, 15, 17  2.1 Toxins 2010, 2                                       
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Summarized from: [18,124–128]. 
3. Binding of Staphylococcus aureus Enterotoxins to MHC II and the TCR 
The primary peptide sequence of the SEs show significant variation [20], and the three dimensional 
structure of at least ten of them have been solved by crystallography: SEA [6], SEB [21,22], SEC2 [23], 
SEC3  [24], SED [10], SEG [25], SEH [26], SEI [27], SEK [28]  and TSST-1  [29]. Although 
differences in SE structure are evident, the similarities are notable despite a lack of primary sequence 
homology. Staphylococcal enterotoxins are typically ellipsoid with two unequal domains including a  
B domain, which is the smallest and associated with carbohydrate binding. The characteristic SE 
disulfide bond is in the domain B and opposes the α-helical cap. The larger A domain contains both the 
amino and carboxyl ends and the interface between A and B contain α-helices which form a long 
groove on the back side of the molecule creating a shallow cavity at the top.  
The structural basis for SE immunological activity has been revealed by mutagenesis and confirmed 
by co-crystallization with TCR-β Chain [22,24,26,28,30]. The binding of SE to TCR depends on the 
shallow cavity at the top of the molecule. This cavity is thought to interact with three loops of the TCR 
Vβ, and the contact residues are from three distant regions of the primary sequence brought into 
proximity with each other in the folded protein. These amino acids are not highly conserved and may 
account for the SE specificity of Vβ. Crystallization of MHC II with SE reveal examples of   
MHC-peptide dependent binding [31–33], MHC-peptide independent binding [34], and finally both 
types of binding [35,36]. These mutational and functional analyses show structural dependencies 
concerning how SE activate T cells, which may provide new avenues for averting immune-based 
diseases mediated by SE. Lastly, recent comprehensive reviews detail the structural features of SAg 
and SAg like proteins including the properties of SAg binding to MHC and TCR [18,37]. 
4. How SE Affects Immune T Cell Tolerance 
A hallmark of in vivo S. aureus enterotoxin responses is the manifestation peripheral T cell clonal 
expansion followed by deletion or programmed death of T cells responding to specific SAg [38,39]. 
This activation-induced cell death (AICD) response can be blocked when the host concomitantly 
responds to bacterial lipopolysaccharide [40], consistent with the recent finding that heightened IL-6 
signaling can also inhibit SEB-induced T cell peripheral deletion [41]. While IL-6 signaling is known 
to induce naïve T cell survival [42], it was nevertheless shown that gp130 signaling (IL-6 receptor 
pathway) within SAg-specific T cells themselves does not block AICD [43]. They demonstrated that 
IL-6 signaling instead impeded Gr-1
+ CD8 T cells from synthesizing IFN-γ, a cytokine central in   
SAg-based T cell tolerance [44]. Atsumi et  al., concluded that CD8 T cells synthesizing IFN-γ 
controlled CD4
+ T cell AICD, but the effector molecule was unlikely to be IFN-γ since addition of 
IFN-γ did not increase cell death [43]. The death effector molecule remains an outstanding question in 
the S. aureus enterotoxin field, although using non-superantigen systems a combined role for both 
TNF receptor and CD95 for AICD of T cells has been documented in vitro [45], and in vivo [46]. 
Although S. aureus enterotoxins induce profound AICD there typically remains a subset of specific 
T cells that fail to delete [47,48] and their function has been the subject of many studies [49]. Perhaps 
their durability and anergic phenotype is an outcome of multiple TCR Vβ hits, but this effect is best Toxins 2010, 2                                       
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observed after repeated injections of SEB. For example, three in vivo injections of SEB gives rise to 
CD4 CD25 T cells expressing Foxp3 protein, which can suppress via dendritic cells by the CD152 
pathway [50]. A second study used a similar approach but discovered a novel CD25 negative CD4 T 
cell population expressing both Foxp3 and GRAIL [51]. Nevertheless, there is in vivo evidence for 
intrinsic anergy programming in the absence of Tregs after repeated SEB injection [52]. Thus, deletion 
and autonomous anergy are natural mechanisms that prevent hyper-responsiveness  of  T cells to   
S. aureus enterotoxins. An excellent clinical role for these pathways was recently revealed in a model 
of OVA-induced airway allergy [53]. The authors demonstrated that SEA pre-treatment in neonates 
enhanced OVA oral tolerance, which conferred protection against intranasal OVA challenge when the 
mice enter adulthood. The mechanism may involve an increase of CCR9-bearing Tregs but otherwise 
remains largely elusive. This is an illustrative example of how S. aureus  (enterotoxin) can drive 
clinically beneficial tolerance. There are numerous examples of how SAgs are involved in disease 
progression [54], but a recent study demonstrated that orally-administered SEB mediated pathology in 
an adoptive transfer model of inflammatory bowel disease only when Tregs were absent [55]. 
Importantly, these results show that expansion of specific-TCR Vβ T cells in Chron’s patients may be 
a function of SAg exacerbating already established disease [56]. Therefore, S. aureus enterotoxins can 
induce Tregs for useful purposes, and conversely Tregs can also inhibit S. aureus  enterotoxin  
mediated pathology. 
5. The Mechanism of How SE Impacts Lung Immune Responses and Disease 
The powerful immune response driven by SAgs discussed above poses other significant health risks 
to humans. Staphylococcal enterotoxins are currently listed on the CDC category B select agent list 
because of its potential to be used as a biological threat. Perhaps this is most evident by its propensity 
to rapidly mediate debilitating pulmonary responses after inhalation in people as observed in one 
known case of an accidental laboratory exposure of SEB [91]. The most recent developments 
concerning clinical issues, however, are results that link SE to asthma and other respiratory ailments 
[92]. It stands to reason that if SAgs drive such robust T cell responses in the periphery and intestinal 
mucosa, then their access to pulmonary sites is all the more serious. In general, this link is based on 
colonization of S. aureus in nasal polyps (NP) [93], which contain extensive expansion of skewed 
repertoires of TCR Vβ-possessing T cells [94]. In clinical studies this has been associated with severe 
upper and lower respiratory disease [95]. In fact, recent data show that some patients with chronic 
sinusitis/nasal polyposis produce IgE specific to S. aureus enterotoxins [96,97], and there is the same 
IgE association in some patients suffering from chronic obstructive pulmonary disease [98]. Secondly, 
the potential disease mechanism of S. aureus enterotoxin in nasal polyps may be the observed high 
level of IL-6 [99], which is known to contribute to Treg inhibition [100]. This is similar to human 
airway smooth cells which effectively present SE to T cells [101]. Importantly, human airway smooth 
cells synthesize IL-6 after CD40 stimulation [102], which is a key T cell based costimulatory pathway. 
Collectively, these human studies reveal the associated risks with exposure to SAg in pulmonary sites. 
A very severe pulmonary  illness difficult to study is the human medical condition status 
asthmaticus. Status asthmaticus is an acute and severe induction of asthma, and is thought to be 
triggered by a variety of lung irritants [103]. Ultimately, this condition is refractory to standard Toxins 2010, 2                                       
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treatments such as steroids as recently reviewed [103]. Similar to patients experiencing a sudden 
asthmatic attack, which may occur in hours and be fatal [104], it is possible that disease onset is 
potentially linked to a role for SE as well as viral infection. A key observation in victims of fatal 
asthma is the appearance of CD8 T cells in the bronchial airways possessing cytotoxic ability as 
indicated by expression of perforin [105]. This is similar to a recent study examining peripheral blood 
responses in patients with mild to severe asthma during periods of exacerbation demonstrating that the 
patients with severe asthma possessed the highest levels of CD8 memory T cells with a Type 1 
cytokine response as opposed to the expected Type 2 cytokine response [106]. New evidence shows 
that S. aureus which produce enterotoxins A-C can strongly stimulate IL-17 production by human 
memory T cells but not naïve [107], and this may contribute to toxic cytokine levels. Also, in a 
postmortem lung study of fatal asthma an increase of CD8 T cells containing cytotoxic abilities in 
bronchi were detected [105]. Consistent with CD8 T cell function and Type-1 cytokines a new report 
detected higher levels of nuclear NFκB in lung epithelial and parenchymal cells from patients that had 
died from fatal asthma compared to control lungs [108]. Lastly, the presence of a skewed TCR Vβ 
repertoire specific for SE in cells of bronchoalveolar lavage (BAL) from patients with poorly 
controlled asthma has been observed previously [109]. While these data are consistent with a potential 
link of SE or SAg playing a role in fatal asthma more proof will be needed and perhaps mouse models 
can play a role in helping clarify this issue.  
In mouse models of SEB intranasal (i.n.) administration, Herz et al., demonstrated that SEB induces 
allergic airway disease in both BALB/c and C57BL/6 mice in a CD4
+ T cell-dependent manner [110]. 
Importantly, repeated SEB i.n. exposure mediated classic allergic airway disease marked by increased 
inflammatory cells in BAL capable of producing pro-inflammatory cytokines, and enhanced airway 
responsiveness to methacholine challenge. This study provided an important link to human asthma and 
further demonstrated how SE can increase pulmonary inflammation. Further, a mouse expressing 
human HLA-DR3 extended these observations by showing that the higher dose of SEB dictates disease 
outcome from eosinophilic to neutrophilic infiltration [111]. The higher SEB i.n. dose (neutrophilic 
infiltration) caused systemic shock resulting in markedly increased levels of   
proinflammatory cytokines in serum and expansion of Vβ8 bearing T cells in spleen [112]. In addition, 
increased  gene transcription of IL-5, IL-4, IFN-γ, IL-12 p40 in bronchi, elevated titers of   
OVA-specific and total IgE in serum, demonstrated that SEB exposure exacerbated or facilitated 
allergic inflammation in an airway disease mouse model perhaps through a dendritic cell-based process 
[113,114]. Therefore, SEB i.n. application in mouse provides a valuable research approach to model 
human pulmonary disease.  
Our recent work tested i.n. SEA exposure instead of SEB to examine other potential outcomes of 
pulmonary immune responses [115]. Histological evidence showed an impressive alveolitis marked by 
protein leakage as measured in BAL and increased levels of innate cells. Within days histopathology 
apparently resolved with decreases in protein and cells in BAL, but it is unclear if pathology such as 
collagen deposition would ensue as a result of this acute response. A striking accumulation of   
SEA-specific CD8 T cells in lung was evident, which was dependent upon CD4 T cells. Importantly, a 
concurrent accumulation of CD11c MHC II high cells dramatically increased in lung after i.n. SEA, 
which were shown to be largely derived from blood [116]. From a mechanistic perspective, it is clear 
that IFN-γ played a critical role in mediating alveolitis but not protein leakage. Thus, the i.n. SEA Toxins 2010, 2                                       
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model show similarities to acquired respiratory distress syndrome or acute lung injury[117]. In a model 
of indirect acute lung injury CD4 T cells were specifically recruited to lung in an IL-16 dependent 
manner after hemorrhagic shock followed by septic challenge [118]. Importantly, these investigators 
found that Foxp3
+ CD4 T regulatory cells played a key role in blocking neutrophil recruitment to lung 
via an IL-10 dependent process. These studies underscore the need for further investigation of systems 
that model human acute lung injury or acquired respiratory distress syndrome, which suggest a more 
prominent role for T cells in disease pathology. 
6. Conclusions and Future Avenues of Investigation 
Thus, the SE i.n. mouse models demonstrate how SAg stimulation of T cells affect airway, alveolar, 
and systemic sites of the body after inhalation exposure. Nevertheless, a number of important 
questions remain with perhaps the most obvious being how does a mitogenic T cell response cause 
such dramatic changes in the innate immune system as seen in the mouse models and human cases as 
discussed above. Certainly, it is reasonable to argue that a cytokine storm may play an important role, 
and there is a solid case for IL-2 being central to this idea. Recently, it was demonstrated that IL-2 
deficient mice were resistant to SEB induced toxic shock unless the mice were reconstituted with IL-2 
[119]. In addition, Chau et al.,  demonstrated that toll-like receptor 2 (TLR2) ligands from the 
Staphylococcal cell wall inhibited SEB-based human T cell activation by reducing IL-2 production. 
This inhibitory effect resulted from a TLR2/peptidoglycan induction of IL-10, which also functioned 
in an in vivo mouse model [120]. This shows that IL-2 is central to a T cell-dependent cytokine shock 
response, but does not necessarily explain how this response conditions cells in the innate immune 
system. In particular, we found that after a SAg response, cells of the innate immune system possessed 
greater ability to respond to TLR ligands [121,122]. This conditioning was also evident through TLR 
pathways cross-talking to TLR non-responsive cells [123]. Therefore, in addition to cytokines it is 
possible that other factors are involved in accentuating the immune response beside IL-2. 
We would like to suggest that another by-product of T cell stimulation such as the generation of 
endogenous danger-associated molecular patterns (DAMPS) may participate in amplifying a lung 
damaging response. This is perhaps a “T cell guided” innate response initiated by T cell killing and 
release of self proteins or lipids that are not normally detected in the steady state but when present are 
able to trigger inflammasome stimulation or TLR pathways in innate cells. This may produce a 
cytokine storm that most studies find and may in-turn further push innate cell activation. Second, the 
type and amount of DAMP generated may also be a biomarker of the magnitude of lung pathology and 
could perhaps be extrapolated to the seriousness of injury. An important point in this regard is that 
tissue fluid from the lung would likely have to be analyzed by techniques other than gene microarray 
since release of the DAMPs would most likely be a product of cell damage. While this idea is 
speculative it may be a pivot point to ascertain how a T cell mitogen can so potently condition the 
innate immune system.  
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